Pemetrexed disodium for injection and preparation method thereof
By optimizing the formula and preparation process of pemetrexed disodium and combining three-time lyophilization processes with egg yolk lecithin, cholesterol and other ingredients, the drug's easy degradation problem under high temperature, humidity and light is solved, and the stability and redissolution are improved. Clarity reduces production and medical costs.
Patent Information
- Application Number
- CN202411052555.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-12
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-19
AI Technical Summary
The existing anti-tumor drug pemetrexed disodium is prone to degradation under high temperature, oxidation, light and humidity conditions, resulting in poor stability and medical risks. It is prone to turbidity after redissolution of freeze-dried products, affecting the effectiveness of medication.
Using the formula consisting of pemetrexed disodium, egg yolk lecithin, cholesterol, sorbitan sesquioleate, pyrrolisine, mannitol and chitosan, the preparation method is optimized through the three-time lyophilization process and the appropriate buffer is selected. Solution and freeze-drying temperature improve the stability of the drug and redissolution clarity.
It significantly improves the stability of pemetrexed disodium, reduces drug waste, shortens production time, reduces medical costs, ensures the stability of the drug under high temperature, high humidity and light conditions, and avoids drug redissolution after The problem of turbidity.
Smart Images

Figure CN118975992A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of anti-tumor drug preparations, and specifically relates to pemetrexed disodium for injection and a preparation method thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Pemetrexed disodium is an anti-tumor drug commonly used to treat various malignant tumors such as non-small cell lung cancer, pleural mesothelioma and metastatic thymoma. Non-small cell lung cancer is a type of lung cancer, including multiple subtypes such as adenocarcinoma, squamous cell carcinoma and large cell carcinoma. It usually grows slowly. Compared with small cell lung cancer, its cells are larger and have better tolerance to chemotherapy and radiotherapy, but early diagnosis is more difficult and can often only be found in the late stage. Mesothelioma is a rare malignant tumor derived from mesothelial tissue. The most common type is pleural mesothelioma. Mesothelioma is usually related to asbestos exposure, with a long incubation period. There are often no obvious symptoms in the early stage. When clinical symptoms appear, the tumor may be in the late stage. Pemetrexed disodium is a multi-target inhibitor that mainly inhibits multiple key enzymes in the folate metabolic pathway, such as methyl-tetrahydrofolate reductase, dihydrofolate synthetase and methyl-dihydrofolate dehydrogenase, thereby blocking the synthesis of DNA and RNA, inhibiting the proliferation and growth of cancer cells. It can also be used in combination with other chemotherapy drugs such as cisplatin to improve the efficacy. Pemetrexed disodium was originally developed by Eli Lilly and Company and was approved by the U.S. FDA for the treatment of non-small cell lung cancer in 2004. It is usually supplied in the market in the form of lyophilized powder injection, which needs to be administered intravenously after preparing the solution before clinical use.
[0004] Pemetrexed disodium is a white to off-white crystalline powder that is soluble in water and weakly acidic. It is generally unstable and easily degraded under high temperature, oxidation, light, and humidity conditions, producing impurities that may cause toxic side effects.
[0005] The Chinese patent with publication number CN 107837237A discloses a pemetrexed disodium pharmaceutical composition and its preparation method, which contains pemetrexed disodium, a stabilizer and an excipient, wherein the weight ratio of pemetrexed disodium to the stabilizer is 50:0.5-5.0, and the weight ratio of pemetrexed disodium to the excipient is 50:5-50, the stabilizer is selected from methionine, and the excipient is selected from mannitol. The Chinese patent with publication number CN 101411710A discloses a pemetrexed disodium lyophilized powder injection, which is composed of pemetrexed disodium 50, mannitol 10-50, sodium sulfite 0.1-1, and the pH value is 7.0-8.0. The above two pemetrexed disodium injections have high impurity content and there is a risk of medication.
[0006] A Chinese patent with publication number CN 103006584 A discloses a method for preparing pemetrexed disodium for injection, comprising the following steps: (1) weighing lactose, adding half amount of water for injection, heating to 40°C to dissolve, and obtaining an auxiliary material solution at a temperature of 40°C; (2) adding 20 g of activated carbon, stirring for 30 minutes, and filtering out the activated carbon;
[0007] (3) Weigh the pemetrexed disodium raw material, add it to the above-mentioned decarbonized auxiliary material solution, and stir it quickly until it is completely dissolved; (4) Add water for injection to 19L, adjust the pH value to 6.8-7.4 with sodium hydroxide or hydrochloric acid, and add water for injection to 20L; (5) After filling, freeze-dry using vacuum freeze-drying technology. The freeze-drying process is: pre-freezing temperature is -40C, 2 hours, sublimation drying time is 18 hours, analytical drying time is 3 hours, and the total time is 23 hours. This technical solution improves the stability of pemetrexed disodium injection to a certain extent. Summary of the invention
[0008] To overcome the deficiencies of the prior art, the present invention provides a highly stable pemetrexed disodium for injection composed of pemetrexed disodium, egg yolk lecithin, cholesterol, sorbitan sesquioleate, pyrrolysine, mannitol and chitosan.
[0009] Specifically, the technical solution of the present invention is as follows:
[0010] The invention provides pemetrexed disodium for injection, which comprises 1.5-3.5 parts by weight of pemetrexed disodium, 3-5 parts by weight of egg yolk lecithin, 0.5-1.5 parts by weight of cholesterol, 0.3-0.8 parts by weight of sorbitan sesquioleate, 0.1-0.5 parts by weight of pyrrolysine, 3-8 parts by weight of mannitol and 2-4 parts by weight of chitosan.
[0011] The preparation method of pemetrexed disodium for injection is as follows:
[0012] (1) Dissolve pyrrolysine and pemetrexed disodium in an appropriate amount of water and prefreeze at -20℃~-28℃ for 2~4h. - 4 pa was sublimated and dried for 3-5 hours, and then heated to room temperature and dried for 3-5 hours to obtain pemetrexed disodium lyophilized powder;
[0013] (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in an organic solvent, add the lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add a buffer solution to adjust the pH to 5.8-6.5, evaporate under reduced pressure in a water bath at 35°C-55°C, remove the solvent, and prefreeze at -15°C-25°C for 2-4 hours, 5×10 -4 pa was sublimated and dried for 3-5 h, and then heated to room temperature and dried for 3-5 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0014] (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into an ampoule, sterilized, and pre-frozen at 5°C to -5°C for 1 to 2 hours. 5×10 -4 pa sublimation drying for 1 to 3 hours, then at -20℃ to -28℃, 5×10 -4 Freeze-dry pa for 1 to 3 hours, heat to room temperature and dry for 3 to 5 hours, seal the container, and you are done.
[0015] Furthermore, the organic solvent is one of n-butanol, ethanol and methanol. Generally speaking, freeze-dried products have the defect of becoming turbid after reconstitution, especially the careless selection of solvents, which makes it easier to have the problem of turbidity after reconstitution. The present invention selects the formula and optimizes the preparation process. After selecting n-butanol, ethanol and methanol as solvents, the pemetrexed disodium for injection prepared is turbid after reconstitution, which solves the major technical problem that freeze-dried products are prone to turbidity after reconstitution.
[0016] The optimization of the preparation process, in addition to the selection of the above-mentioned solvent, also includes the selection of buffer solution and pH, and the setting of temperature and time for each freeze-drying stage.
[0017] Furthermore, the buffer solution is one of a phosphate buffer solution, a citrate buffer solution, and a carbonate buffer solution.
[0018] In a preferred embodiment,
[0019] The pemetrexed disodium for injection is composed of 2.5 parts by weight of pemetrexed disodium, 4 parts by weight of egg yolk lecithin, 1 part by weight of cholesterol, 0.6 parts by weight of sorbitan sesquioleate, 0.3 parts by weight of pyrrolysine, 5 parts by weight of mannitol, and 3 parts by weight of chitosan.
[0020] The preparation method of pemetrexed disodium for injection is as follows:
[0021] (1) Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -25°C for 3 h, and freeze 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium lyophilized powder;
[0022] (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in n-butanol, add lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add phosphate buffer solution to adjust pH to 6.2, evaporate under reduced pressure in a water bath at 45°C, remove the solvent, and prefreeze at -20°C for 3h, 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0023] (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at 0°C for 1.5 h. 5×10 -4 pa was sublimated and dried for 2 h, then at -22 °C, 5 × 10 -4 Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
[0024] Compared with the prior art, the technical effects of the present invention are:
[0025] The preferred formula of the present invention complements the preparation process, especially the three-time freeze-drying process is adopted, which improves the stability of the pemetrexed disodium injection. Accelerated tests and illumination experiments prove that the content of the pemetrexed disodium for injection of the present invention is stable and the content of related substances is low, which solves the problem that pemetrexed disodium is easily decomposed and degraded under high temperature, high humidity and illumination conditions to a certain extent, can reduce drug waste and save medical costs.
[0026] The shortest preparation time of the present invention can be 8 hours, which greatly shortens the production time compared with the prior art, is suitable for industrial production, can reduce production costs, thereby reducing medical costs and improving the effective use of resources. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is the content stability curve of pemetrexed disodium for injection in the accelerated test.
[0028] Figure 2 This is the content stability curve of pemetrexed disodium for injection in the light test. DETAILED DESCRIPTION
[0029] In order to make the purpose and technical solution of the present invention clearer, the present invention is further described below in conjunction with embodiments, but the protection scope of the present invention is not limited to these embodiments, and the embodiments are only used to explain the present invention. It should be understood by those skilled in the art that any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.
[0030] Example 1 Pemetrexed disodium for injection
[0031] Components:
[0032] Weight(g) Pemetrexed disodium 2.5 Egg yolk lecithin 4 cholesterol 1 Sorbitan sesquioleate 0.6 Pyrrolysine 0.3 Mannitol 5 Chitosan 3
[0033] Preparation method:
[0034] (1) Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -25°C for 3 h, and freeze 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium lyophilized powder;
[0035] (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in n-butanol, add lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add phosphate buffer solution to adjust pH to 6.2, evaporate under reduced pressure in a water bath at 45°C, remove the solvent, and prefreeze at -20°C for 3h, 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0036] (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at 0°C for 1.5 h. 5×10 -4 pa was sublimated and dried for 2 h, then at -22 °C, 5 × 10 -4 Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
[0037] Example 2 Pemetrexed Disodium for Injection
[0038] Components:
[0039] Weight(g) Pemetrexed disodium 1.5 Egg yolk lecithin 3 cholesterol 0.5 Sorbitan sesquioleate 0.3 Pyrrolysine 0.1 Mannitol 3 Chitosan 2
[0040] Preparation method:
[0041] (1) Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -20℃ for 2h, and freeze 5×10 -4 pa was sublimated and dried for 3 h, and then heated to room temperature and dried for 3 h to obtain pemetrexed disodium lyophilized powder;
[0042] (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in an organic solvent, add the lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add a buffer solution to adjust the pH to 5.8, and perform vacuum rotary evaporation in a water bath at 35°C to remove the solvent, and then prefreeze at -15°C for 2h, 5×10 -4 pa was sublimated and dried for 3 h, and then heated to room temperature and dried for 3 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0043] (3) The lyophilized powder of pemetrexed disodium liposome prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at 5°C for 1 hour. 5×10 -4 pa was sublimated and dried for 1 h, then at -20 °C, 5 × 10 -4 Freeze-dry pa for 1 h, heat to room temperature and dry for 3 h, seal the container, and you’re done.
[0044] Example 3 Pemetrexed disodium for injection
[0045] Components:
[0046] Weight(g) Pemetrexed disodium 3.5 Egg yolk lecithin 5 cholesterol 1.5 Sorbitan sesquioleate 0.8 Pyrrolysine 0.5 Mannitol 8 Chitosan 4
[0047] Preparation method:
[0048] (1) Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -28°C for 4 h, and 5×10 -4 pa was sublimated and dried for 5 h, and then the temperature was raised to room temperature and dried for 5 h to obtain pemetrexed disodium lyophilized powder;
[0049] (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in an organic solvent, add the lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add a buffer solution to adjust the pH to 6.5, evaporate under reduced pressure in a water bath at 55°C, remove the solvent, and then prefreeze at -25°C for 4h, 5×10 -4 pa was sublimated and dried for 5 h, and then heated to room temperature and dried for 5 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0050] (3) The lyophilized powder of pemetrexed disodium liposome prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at -5°C for 2 h. 5×10 -4 pa was sublimated and dried for 3 h, then at -28 °C, 5 × 10 -4 Freeze-dry pa for 3 h, heat to room temperature and dry for 5 h, seal the container, and you’re done.
[0051] Comparative Example 1 Pemetrexed Disodium for Injection
[0052] Components:
[0053] Weight(g) Pemetrexed disodium 2.5 Egg yolk lecithin 4 cholesterol 1 Pyrrolysine 0.3 Mannitol 5 Chitosan 3
[0054] Preparation method:
[0055] (1) Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -25°C for 3 h, and freeze 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium lyophilized powder;
[0056] (2) Dissolve egg yolk lecithin and cholesterol in n-butanol, add lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add phosphate buffer solution to adjust pH to 6.2, evaporate under reduced pressure in a water bath at 45°C, remove the solvent, and prefreeze at -20°C for 3h, 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0057] (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at 0°C for 1.5 h. 5×10 -4 pa was sublimated and dried for 2 h, then at -22 °C, 5 × 10 -4 Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
[0058] Comparative Example 2 Pemetrexed Disodium for Injection
[0059] Components:
[0060] Weight(g) Pemetrexed disodium 2.5 Egg yolk lecithin 4 cholesterol 1 Sorbitan sesquioleate 0.6 Mannitol 5 Chitosan 3
[0061] Preparation method:
[0062] (1) Dissolve pemetrexed disodium in an appropriate amount of water and prefreeze at -25°C for 3 h. -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium lyophilized powder;
[0063] (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in n-butanol, add lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add phosphate buffer solution to adjust pH to 6.2, evaporate under reduced pressure in a water bath at 45°C, remove the solvent, and prefreeze at -20°C for 3h, 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0064] (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at 0°C for 1.5 h. 5×10 -4 pa was sublimated and dried for 2 h, then at -22 °C, 5 × 10 -4 Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
[0065] Comparative Example 3: Pemetrexed disodium for injection
[0066] Components:
[0067] Weight(g) Pemetrexed disodium 2.5 Egg yolk lecithin 4 cholesterol 1 Sorbitan sesquioleate 0.6 Lysine 0.3 Mannitol 5 Chitosan 3
[0068] Preparation method:
[0069] (1) Dissolve lysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -25℃ for 3h, and freeze 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium lyophilized powder;
[0070] (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in n-butanol, add lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add phosphate buffer solution to adjust pH to 6.2, evaporate under reduced pressure in a water bath at 45°C, remove the solvent, and prefreeze at -20°C for 3h, 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0071] (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at 0°C for 1.5 h. 5×10 -4 pa was sublimated and dried for 2 h, then at -22 °C, 5 × 10 -4 Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
[0072] Comparative Example 4: Pemetrexed Disodium for Injection
[0073] Components:
[0074] Weight(g) Pemetrexed disodium 2.5 Egg yolk lecithin 4 cholesterol 1 Sorbitan sesquioleate 0.6 Pyrrolysine 0.3 Mannitol 5 Chitosan 3
[0075] Preparation method:
[0076] (1) Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -25°C for 3 h, and freeze 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium lyophilized powder;
[0077] (2) Egg yolk lecithin, cholesterol, and sorbitan sesquioleate were dissolved in n-butanol, and the lyophilized powder of pemetrexed disodium prepared in step (1) was added and fully dissolved. A phosphate buffer solution was added to adjust the pH to 6.2, and the mixture was evaporated under reduced pressure in a water bath at 45°C to remove the solvent. Mannitol and chitosan were added and fully mixed. The mixture was filled into an ampoule and sterilized. The mixture was pre-frozen at 0°C for 1.5 h, and 5×10 -4 pa was sublimated and dried for 2 h, then at -22 °C, 5 × 10-4 Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
[0078] Comparative Example 5: Pemetrexed Disodium for Injection
[0079] Components:
[0080] Weight(g) Pemetrexed disodium 2.5 Egg yolk lecithin 4 cholesterol 1 Sorbitan sesquioleate 0.6 Pyrrolysine 0.3 Mannitol 5 Chitosan 3
[0081] Preparation method:
[0082] Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, dissolve egg yolk lecithin, cholesterol and sorbitan sesquioleate in n-butanol, mix thoroughly and dissolve, add phosphate buffer solution to adjust pH=6.2, evaporate under reduced pressure in a water bath at 45℃ to remove the solvent, add mannitol and chitosan, mix thoroughly, fill in ampoules, sterilize, pre-freeze at 0℃ for 1.5h, 5×10 - 4 pa was sublimated and dried for 2 h, then at -22 °C, 5 × 10 -4 Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
[0083] Comparative Example 6 Pemetrexed Disodium for Injection
[0084] Components:
[0085]
[0086]
[0087] Preparation method:
[0088] (1) Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -25°C for 3 h, and freeze 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium lyophilized powder;
[0089] (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in n-butanol, add the lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add phosphate buffer solution to adjust the pH to 7.2, evaporate under reduced pressure in a water bath at 45°C, remove the solvent, and then prefreeze at -10°C for 3h, 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium liposome freeze-dried powder;
[0090] (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at 0°C for 1.5 h. 5×10 -4 pa was sublimated and dried for 2 h, then at -10 °C, 5 × 10 -4Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
[0091] Stability verification of pemetrexed disodium for injection
[0092] According to the guidelines for stability testing of raw materials and preparations in Part 2, 9001 of the 2020 edition of the Chinese Pharmacopoeia, the pemetrexed disodium for injection of Examples 1 to 3, Comparative Examples 1 to 6, and commercially available pemetrexed disodium for injection (National Medicine Standard H20203051) were used as test samples to determine the content and related substances.
[0093] The relevant substances were determined according to the high performance liquid chromatography method. The test sample was taken, dissolved in water and made into a solution containing 0.5 mg per 1 ml as the test solution; 2 ml was accurately measured and placed in a 100 ml volumetric flask, diluted to the mark with water and shaken well as the control solution; octadecylsilane bonded silica gel was used as the filler, phosphoric acid solution (11 ml of phosphoric acid was taken, 800 ml of water was added, the pH value was adjusted to 2.3 with triethylamine, and diluted to 1000 ml with water) was used as the mobile phase A; acetonitrile was used as the mobile phase B; the flow rate was 1.5 ml per minute; the detection wavelength was 215 nm; gradient elution was performed according to the table below; the theoretical plate number should be not less than 1500 based on the pemetrexed disodium peak. 50 μl of the control solution was injected into the liquid chromatograph, and the detection sensitivity was adjusted so that the main component chromatographic peak height was about 20% of the full scale; 50 μl of the test solution and the control solution were accurately measured and injected into the liquid chromatograph respectively, and the chromatogram was recorded. If there are impurity peaks in the chromatogram of the test solution, except for the solvent peak, the area of a single impurity peak shall not be greater than half of the main peak area of the control solution (1.0%); the sum of the areas of all impurity peaks shall not be greater than the main peak area of the control solution (2.0%).
[0094] Table 1 Elution conditions
[0095]
[0096] The stability test of pemetrexed disodium for injection is divided into two conditions for verification, one is the accelerated test and the other is the light test. The accelerated test conditions are: temperature 40±2℃, relative humidity 75%±5% for 6 months; the light test conditions are: placed under 4500lx±500lx for 6 months.
[0097] Samples were collected on the first day, at the end of the first month, at the end of the third month, and at the end of the sixth month of the trial, and the content of pemetrexed disodium and related substances were detected by high performance liquid chromatography.
[0098] Table 2 Total content of related substances in pemetrexed disodium for injection in accelerated test and illumination test
[0099]
[0100]
[0101] As shown in Table 2, pemetrexed disodium is intolerant to high temperature, high humidity and light. Especially under light conditions, pemetrexed disodium produces more related substances, so the commercially available pemetrexed disodium for injection needs to be shading, airtight, and refrigerated at 2-8°C to avoid the degradation of pemetrexed disodium to produce related substances. The pemetrexed disodium for injection in Examples 1-3 of the present invention alleviates the problem that pemetrexed disodium is prone to generate related substances when exposed to high temperature, high humidity and light, and significantly improves the stability of pemetrexed disodium for injection.
[0102] The content of pemetrexed disodium was determined by high performance liquid chromatography. The chromatographic conditions and system suitability test were as follows: octadecylsilane bonded silica gel was used as filler; phosphoric acid solution (take 11 ml of phosphoric acid, add 800 ml of water, adjust the pH to 2.3 with triethylamine, and dilute to 1000 ml with water) ~ acetonitrile (75:25) was used as mobile phase; the flow rate was 1.5 ml per minute; the detection wavelength was 215 nm; the number of theoretical plates calculated based on the pemetrexed disodium peak should not be less than 1500; determination method: take the test sample, add appropriate amount of water respectively, dissolve the contents and quantitatively dilute to make a solution containing about 0.1 mg per 1 ml, mix and shake well, as the test solution; accurately measure 20 μl and inject into the liquid chromatograph, record the chromatogram; take an appropriate amount of pemetrexed disodium reference substance to make a solution containing about 0.1 mg per 1 ml, determine in the same way, and calculate by peak area according to the external standard method to obtain the result.
[0103] Figure 1 This is the content stability curve of pemetrexed disodium for injection in the accelerated test. Figure 2 The content stability curve of pemetrexed disodium for injection in the light test is shown in FIG. The results show that the pemetrexed disodium for injection of the present invention can remain stable in a high temperature, high humidity and light environment, and the pemetrexed disodium remains basically unchanged.
[0104] Verification of the reconstitution properties of pemetrexed disodium for injection
[0105] The pemetrexed disodium for injection of Examples 1 to 3 and Comparative Examples 1 to 6 were redissolved in 0.9% sodium chloride solution, and the clarity, color, and visible foreign matter were observed, and the pH was measured.
[0106] Table 3 Verification of reconstitution properties of pemetrexed disodium for injection
[0107] Visible foreign matter Clarity pH Example 1 qualified Colorless clear liquid 6.2 Example 2 qualified Colorless clear liquid 5.9 Example 3 qualified Colorless clear liquid 6.6 Comparative Example 1 qualified Colorless clear liquid 6.0 Comparative Example 2 qualified Colorless clear liquid 6.2 Comparative Example 3 qualified Colorless clear liquid 6.4 Comparative Example 4 qualified There is a trace of flocculent 6.3 Comparative Example 5 qualified There is a trace of flocculent 6.4 Comparative Example 6 Failure A small amount of flocculent 7.5
[0108] As shown in Table 3, the auxiliary materials of pemetrexed disodium for injection of the present invention are properly matched and complement each other with the preparation process. After the prepared pemetrexed disodium for injection is reconstituted, the foreign matter inspection is qualified, the solution is clear and transparent, and the pH is stable and within the specified range of the injection.
Claims
1. A pemetrexed disodium for injection, characterized in that: The pemetrexed disodium for injection consists of pemetrexed disodium, egg yolk lecithin, cholesterol, sorbitan sesquioleate, pyrrolysine, mannitol and chitosan.
2. The pemetrexed disodium for injection according to claim 1, characterized in that: The pemetrexed disodium for injection is composed of 1.5 to 3.5 parts by weight of pemetrexed disodium, 3 to 5 parts by weight of egg yolk lecithin, 0.5 to 1.5 parts by weight of cholesterol, 0.3 to 0.8 parts by weight of sorbitan sesquioleate, 0.1 to 0.5 parts by weight of pyrrolysine, 3 to 8 parts by weight of mannitol, and 2 to 4 parts by weight of chitosan.
3. The pemetrexed disodium for injection according to claim 1 or 2, characterized in that: The pemetrexed disodium for injection is composed of 2.5 parts by weight of pemetrexed disodium, 4 parts by weight of egg yolk lecithin, 1 part by weight of cholesterol, 0.6 parts by weight of sorbitan sesquioleate, 0.3 parts by weight of pyrrolysine, 5 parts by weight of mannitol, and 3 parts by weight of chitosan.
4. The method for preparing pemetrexed disodium for injection according to claim 1, characterized in that: The preparation method is: (1) Dissolve pyrrolysine and pemetrexed disodium in an appropriate amount of water and prefreeze at -20℃~-28℃ for 2~4h. -4 pa was sublimated and dried for 3-5 hours, and then heated to room temperature and dried for 3-5 hours to obtain pemetrexed disodium lyophilized powder; (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in an organic solvent, add the lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add a buffer solution to adjust the pH to 5.8-6.5, evaporate under reduced pressure in a water bath at 35°C-55°C, remove the solvent, and prefreeze at -15°C-25°C for 2-4 hours, 5×10 -4 pa was sublimated and dried for 3-5 h, and then heated to room temperature and dried for 3-5 h to obtain pemetrexed disodium liposome freeze-dried powder; (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into an ampoule, sterilized, and pre-frozen at 5°C to -5°C for 1 to 2 hours. 5×10 -4 pa sublimation drying for 1 to 3 hours, then at -20℃ to -28℃, 5×10 -4 Freeze-dry pa for 1 to 3 hours, heat to room temperature and dry for 3 to 5 hours, seal the container, and you are done.
5. The preparation method according to claim 4, characterized in that: The organic solvent is one of n-butanol, ethanol and methanol.
6. The preparation method according to claim 4, characterized in that: The buffer solution is one of a phosphate buffer solution, a citrate buffer solution and a carbonate buffer solution.
7. The preparation method according to claim 4, characterized in that: The buffer solution was adjusted to pH=6.
2.
8. The preparation method according to claim 4 or 5, characterized in that: The organic solvent is n-butanol.
9. The preparation method according to claim 4 or 6, characterized in that: The buffer solution is a phosphate buffer solution.
10. The preparation method according to claim 4, characterized in that: The preparation method is: (1) Dissolve pyrrolysine and pemetrexed disodium in appropriate amount of water, pre-freeze at -25°C for 3 h, and freeze 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium lyophilized powder; (2) Dissolve egg yolk lecithin, cholesterol, and sorbitan sesquioleate in n-butanol, add lyophilized powder of pemetrexed disodium prepared in step (1), fully dissolve, add phosphate buffer solution to adjust pH to 6.2, evaporate under reduced pressure in a water bath at 45°C, remove the solvent, and prefreeze at -20°C for 3h, 5×10 -4 pa was sublimated and dried for 4 h, and then heated to room temperature and dried for 4 h to obtain pemetrexed disodium liposome freeze-dried powder; (3) The pemetrexed disodium liposome freeze-dried powder prepared in step (2) was fully mixed with mannitol and chitosan, filled into ampoules, sterilized, and pre-frozen at 0°C for 1.5 h. 5×10 -4 pa was sublimated and dried for 2 h, then at -22 °C, 5 × 10 -4 Freeze-dry pa for 2 h, heat to room temperature and dry for 4 h, seal the container, and you’re done.
